MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Honeywell Quality Management Review helps manufacturers boost efficiency and quality compliance
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management
The emergence of new infections in India is a growing concern
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
